Is JNJ's Innovative Medicine segment outperforming other divisions?

**Johnson & Johnson's Innovative Medicine segment is not currently outperforming other divisions based on the available data.** Here's a detailed analysis:

1. **Revenue Comparison**: The Innovative Medicine segment generated $56.96 billion in revenue, while the Medical Devices segment reported $31.86 billion in revenue. It is clear that the Innovative Medicine segment has a higher revenue figure, which might suggest a stronger performance. However, without specific year-over-year growth rates or other performance metrics, it is challenging to make a definitive assessment of outperformance.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|JNJ|JNJ.N|Johnson & Johnson|20240101-2024|Medical Devices|3.1857E10|169|
|JNJ|JNJ.N|Johnson & Johnson|20240101-2024|Medical Devices|2.3669E10|169|
|JNJ|JNJ.N|Johnson & Johnson|20240101-2024|Medical Devices|1.5778E10|169|
|JNJ|JNJ.N|Johnson & Johnson|20240101-2024|Medical Devices|7.821E9|169|
|JNJ|JNJ.N|Johnson & Johnson|20240101-2024|Medical Devices|7.821E9|169|
|JNJ|JNJ.N|Johnson & Johnson|20240101-2024|Innovative Medicine|1.3562E10|169|

2. **Context is Key**: To determine if the Innovative Medicine segment is outperforming, it would be necessary to compare these figures with the previous year's revenues or with industry averages. Without this context, we can only observe that the Innovative Medicine segment has a higher revenue than the Medical Devices segment.
3. **Other Factors**: Outperformance can also be influenced by factors such as profit margins, return on investment, and market share gains. Without additional information on these aspects, it is not possible to fully assess the outperformance of the Innovative Medicine segment.

In conclusion, while the Innovative Medicine segment of Johnson & Johnson appears to have a higher revenue than the Medical Devices segment, additional context and analysis are required to determine if this constitutes outperformance.